Therapeutic approach to drug resistant tumors

Therapeutic Drug Monitoring

Volumn 20, Issue 5, 1998, Pages 577-580

  Naito, Mikihiko ^a   Tsuruo, Takashi ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

KW 2149; MMC resistance; MS 209; Multidrug resistance; SDZ PSC 833

Indexed keywords

5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; 7 N [2 [[2 (GAMMA GLUTAMYLAMINO)ETHYL]DITHIO]ETHYL]MITOMYCIN C; ANTINEOPLASTIC AGENT; CYCLOSPORIN A; CYSTEINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GLUTATHIONE; GLYCOPROTEIN P; MITOMYCIN C; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MRK 16; PACLITAXEL; QUINOLINE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; UNCLASSIFIED DRUG; VALSPODAR; VINCA ALKALOID; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD BRAIN BARRIER; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CONFERENCE PAPER; CYTOTOXICITY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CYCLOSPORINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MITOMYCIN; P-GLYCOPROTEIN; QUINOLINES;

EID: 0031687875     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199810000-00022     Document Type: Conference Paper

References (39)

1. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989;58:137-71.
2. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62:385-427.
3. Tsuruo T. Mechanism of multidrug resistance and implications for therapy. Jpn J Cancer Res 1988;79:285-96.
4. Hamada H, Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986;83:7785-9.
5. 2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells. J Biol Chem 1988;263:11887-91.
6. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-8.
7. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86:695-8.
8. Sugawara I, Hamada H, Tsuruo T, Mori S. Specialized localization of P-glycoprotein recognized by MRK 16 monoclonal antibody in endothelial cells of the brain and the spinal cord. Jpn J Cancer Res 1990;81:727-30.
9. Naito M, Yusa K, Tsuruo T. Steroid hormones inhibit binding of Vinca alkaloid to multidrug resistance related P-glycoprotein. Biochem Biophys Res Commun 1989;158:1066-71.
10. Yang C-PH, DePinho SG, Greenberger LM, Arceci RJ, Horwitz SB. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem 1989;264:782-8.
11. Ueda K, Okamura N, Hirai M, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992;267:24248-52.
12. Watanabe T, Suzuki H, Sawada Y, et al. Induction of hepatic P-glycoprotein enhances biliary excretion of vincristine in rats. J Hepatol 1995;23:440-8.
13. Hori R, Okamura N, Aiba T, Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 1993;266:1620-5.
14. Kamimoto Y, Gatmaitan Z, Hsu J, Arias IM. The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J Biol Chem 1989;264:11693-8.
15. Tatsuta T, Naito M, Oh-hara T, Sugawara I, Tsuruo T. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 1992;267:20383-91.
16. Shirai A, Naito M, Tatsuta T, et al. Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein. Biochim Biophys Acta 1994;1222:400-4.
17. Tatsuta T, Naito M, Mikami K, Tsuruo T. Enhanced expression by the brain matrix of P-glycoprotein in brain capillary endothelial cells. Cell Growth Differ 1994;5:1145-52.
18. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-72.
19. Rogan AM, Hamilton TC, Young RC, Klecker RWJ, Ozols RF. Reversal of Adriamycin resistance by verapamil in human ovarian cancer. Science 1984;224:994-6.
20. Slater LM, Sweet P, Stupecky M, Gupta S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 1986;77:1405-8.
21. Twentyman PR. Modification of cytotoxic drug resistance by non-immuno-suppressive cyclosporins. Br J Cancer 1988;57:254-8.
22. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991;9:17-24.
23. Sonneveld P, Durie BGM, Lokhorst HM, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 1992;340:255-9.
24. Baba M, Nakanishi O, Sato W, et al. Relationship between multidrug resistant gene expression and multidrug resistant-reversing effect of MS-209 in various tumor cells. Cancer Chemother Pharmacol 1995;36:361-7.
25. Sato W, Fukazawa N, Nakanishi O, et al. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol 1995;35:271-7.
26. Nakanishi O, Baba M, Saito A, et al. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug resistant solid tumor cell lines. Oncol Res 1997;9:61-9.
27. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991;51:4226-33.
28. Boesch D, Muller K, Pourtier-Manzanedo A, Loor F. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivatives. Exp Cell Res 1991;196:26-32.
29. Keller RP, Altermatt HJ, Nooter K, et al. SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 1992;50:593-7.
30. Watanabe T, Tsuge H, Oh-hara T, Naito M, Tsuruo T. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 1995;34:235-41.
31. Naito M, Watanabe T, Tsuge H, Koyama T, Oh-hara T, Tsuruo T. Potentiation of the reversal activity of SDZ PSC833 on multidrug resistance by an anti-P-glycoprotein monoclonal antibody MRK-16. Int J Cancer 1996;67:435-40.
32. Watanabe T, Naito M, Oh-hara T, Itoh Y, Cohen D, Tsuruo T. Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid tumor-bearing mice model. Jpn J Cancer Res 1996;87: 184-93.
33. Naito M, Tsuge H, Kuroko C, et al. Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance. J Natl Cancer Inst 1993;85:311-6.
34. Naito M, Tsuge H, Kuroko C, Tomida A, Tsuruo T. Enhancement of reversing effect of cyclosporin A on vincristine resistance by anti-P-glycoprotein monoclonal antibody MRK-16. Jpn J Cancer Res 1993;84:489-92.
35. Watanabe T, Naito M, Kokubu N, Tsuruo T. Regression of established tumors expressing P-glycoprotein by combination of Adriamycin, cyclosporin derivatives, and MRK-16 antibodies. J Natl Cancer Inst 1997;89:512-8.
36. Mikami K, Naito M, Tomida A, Yamada M, Shirakusa T, Tsuruo T. DT-diaphorase as a critical determinant of the sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res 1996;56:2823-6.
37. Lee JH, Naito M, Nakajima M, Tsuruo T. Isolation and characterization of a mitomycin C-resistant variant of human colon carcinoma HT-29 cells. Cancer Chemother Pharmacol 1993;33:215-20.
38. Morimoto M, Ashizawa T, Ohno H, et al. Antitumor activity of 7-N-{{2-{[2-(γ-L-Glutamylamino)ethyl]dithio}ethyl}}-mitomycin C. Cancer Res 1991;51:110-5.
39. Lee JH, Naito M, Tsuruo T. Nonenzymatic reductive activation of 7-N-{{2-{[2-(γ-L-glutamylamino)ethyl]dithio}ethyl}}mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells. Cancer Res 1994;54:2398-403.